Abstract
Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) emerged in Wuhan, China, in late 2019. This became a global health crisis which caused millions of deaths worldwide. The first official case reported in India on 27th January 2020 in Thrissur, Kerala. The vaccines developed, approved and in function are Covaxin (BBV152), Oxford-AstraZeneca (ChAdOx1nCoV-19), Covishield, PfizerBioNtech and Moderna. These vaccines are still under their respective phases of trials. Their adverse effects are under surveillance. In India these AEFIs are reported to Ministry of Health and Family welfare. The common systemic reactions observed were injection site pain, myalgia, fever, headache and shivering. The delayed and rare side effects reported include dyspnea, ischemia, thrombolysis, anaphylaxis, neuralgias, orofacial symptoms and death. The list of orofacial adverse effects based on the clinical trials include palatal petechiae, herpes zoster, angular cheilitis, mucositis, xerostomia, burning sensation in mouth, dysguesia, oral apthous ulcers, trigeminal neuralgia and facial nerve palsy. Reporting these oral lesions are under the onus of oral medicine experts and this article aims to provide a systematic review of the same.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
